We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




TB Tests May Not Detect Infection in Exposed Individual

By LabMedica International staff writers
Posted on 17 Jul 2019
Print article
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Image: QuantiFERON-TB Gold (QFT) is an innovative blood test that measures the cell-mediated immune response of Mycobacterium tuberculosis infected individuals (Photo courtesy of Qiagen).
Mycobacterium tuberculosis is the leading infectious cause of death worldwide Exposure to M. tuberculosis results in heterogeneous clinical outcomes including primary progressive tuberculosis (TB) and latent tuberculosis infection (LTBI).

M. tuberculosis infection is identified using the tuberculin skin test (TST) and interferon-γ (IFN-γ) release assay (IGRA), and a positive result may prompt chemoprophylaxis to prevent progression to tuberculosis. TST measures a delayed-type hypersensitivity reaction to purified protein derivative of the bacteria (PPD) and IFN-γ distinguishes between bacille Calmette–Guèrin (BCG) vaccination and TB infections.

An international collaboration of infectious disease experts led by the Ragon Institute (Cambridge, MA, USA) recruited 79 Ugandans, and index individuals with pulmonary TB were identified by culture for confirmed pulmonary TB. A total of 2,585 household contacts of these index cases were enrolled and followed prospectively for up to two years, aimed at identifying development of LTBI based on serial TST at 0, 3, 6, 12, 18 and 24 months, or active TB based on clinical signs and symptoms of disease and culture evaluation.

The study’s evaluation for M. tuberculosis infection status consisted of three QuantiFERON-TB Gold assays with the first at enrollment in the re-tracing study, the next two over the next two years, and a TST following the last QFT. QuantiFERON-Gold-In-Tube (QFT-GIT) was used in the present study. A Luminex isotype assay was used to quantify the relative levels of antigen-specific antibody isotypes and subclasses.

The team found 198 individuals (8.2%) who lived in these households for more than 10 years but who never tested positive on the TST or the more modern blood test interferon-gamma release assay. This meant they were either "resistant" to the M. tuberculosis infection or not being detected by the two standard tests. These ‘resisters’ possess IgM, class-switched IgG antibody responses and non-IFN-γ T cell responses to the M. tuberculosis-specific proteins ESAT6 and CFP10, immunologic evidence of exposure to M. tuberculosis. Compared to subjects with classic LTBI, ‘resisters’ display enhanced antibody avidity and distinct M. tuberculosis-specific IgG Fc profiles.

W. Henry Boom, MD, a Professor of Medicine, and a senior author of the study said, “TB remains the leading infectious cause of death worldwide, and for that reason, these findings about natural defenses by a significant sample of 8% of people exposed to TB over more than 10 years is eye-opening. This may point us to a signature among people who appear to be naturally immune that could inform vaccine development. It also is possible that we need to reconsider the standard TB tests to take into consideration for very low-level cases of TB. The study was originally published on May 20, 2019, in the journal Nature Medicine.

Related Links:
Ragon Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.